On Thursday, MiMedx Group Inc (NASDAQ:MDXG)’s shares inclined 5.29% to $11.74.
S&P Dow Jones Indices will make the following changes to the S&P 100, S&P 500, S&P MidCap 400 and S&P SmallCap 600 indices:
S&P 500 constituent The Priceline Group Inc. (PCLN) will replace Baxter International Inc. (BAX) in the S&P 100, Baxalta Inc. (NYSE:BXLTwi) will replace QEP Resources Inc. (QEP) in the S&P 500, QEP Resources will replace Itron Inc. (ITRI) in the S&P MidCap 400, and Itron will replace Arch Coal Inc. (ACI) in the S&P SmallCap 600 after the close of trading on Tuesday, June 30. Baxter International is spinning off Baxalta in a transaction predictable to be accomplished on that date. Baxter International will remain in the S&P 500 following the distribution, but its post spin market capitalization will no longer make it appropriate for the S&P 100. QEP Resources, Itron and Arch Coal are all ranked near or at the bottom of their current indices.
Skechers USA Inc. (SKX) will replace Rock-Tenn Co. (RKT) in the S&P MidCap 400, and MiMedx Group Inc. (MDXG) will replace Skechers USA in the S&P SmallCap 600 after the close of trading on Tuesday, June 30. S&P 500 constituent MeadWestvaco Corp. (MWV) is combining with Rock-Tenn in a transaction predictable to be accomplished on or about that date. The combined company will remain in the S&P 500 and will change its name to WestRock Co.
HealthEquity Inc. (HQY) will replace Zep Inc. (ZEP) in the S&P SmallCap 600 after the close of trading on Thursday, June 25. Private equity firm New Mountain Capital is acquiring Zep in a transaction predictable to be accomplished on or about that date pending final approvals.
The Priceline Group provides online travel and travel related reservation and search services.
Baxalta develops and markets innovative biopharmaceuticals. Headquartered in Deerfield, IL, the company will be added to the S&P 500 GICS (Global Industry Classification Standard) Biopharmaceuticals Sub-Industry index.
MiMedx Group, Inc. develops, processes, and markets patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. Its biomaterial platform technologies are AmnioFix, EpiFix, and CollaFix. The companys AmnioFix and EpiFix are tissue technologies processed from human amniotic membrane derived from donated placentas.
Charter Communications, Inc. (NASDAQ:CHTR)’s shares dropped -0.38% to $167.84.
Charter Communications, Inc. (CHTR) released the following statement from President and CEO Tom Rutledge in response to the passing of Ralph Roberts.
“Ralph was a true cable industry pioneer and Philadelphia gentleman. His contributions to the development and continued success of the cable industry are numerous, and his legacy will endure for generations to come. Our thoughts are with the Roberts family and the entire Comcast organization.”
Charter Communications, Inc., through its auxiliaries, provides entertainment, information, and communications solutions to residential and commercial customers in the United States. The company offers cable video programming services, counting basic and digital video, premium channels, on-demand, pay-per-view, high definition television, and digital video recorder services, in addition to Charter TV App, which enables video customers to search and discover content on various devices, counting the iPhone, iPad, iPod Touch, and Android based tablets.
At the end of Thursday’s trade, Cyberark Software Ltd (NASDAQ:CYBR)‘s shares dipped -0.20% to $69.75.
Cyberark Software Ltd (CYBR) the company that protects organizations from cyber attacks that have made their way inside the network perimeter, declared details of its forthcoming webinar, “30-Day Cybersecurity Sprint: Tightening Privileged User Policies.” The session will outline the cybersecurity initiative from the White House and U.S. Federal CIO Tony Scott, and explore how agencies can better protect sensitive information and assets, and make it more difficult for hackers to gain access to federal systems.
CyberArk Software Ltd. develops, markets, and sells software-based IT security solutions that protect organizations from cyber attacks in the United States and internationally. The company offers privileged account security solution to secure, manage, and monitor privileged account access and activities. Its privileged account security solution comprises of Enterprise Password Vault that provides a tool to manage and protect physical, virtual, or cloud-based assets; SSH Key Manager to store, rotate, and control access to SSH keys for preventing unauthorized access to privileged accounts; Privileged Session Manager that protects servers, applications, databases, and hypervisors from malware; and Privileged Threat Analytics that profiles and analyzes individual privileged user behavior and creates prioritized alerts when abnormal activity is detected.
Halozyme Therapeutics, Inc. (NASDAQ:HALO), ended its Thursday’s trading session with -0.10% loss, and closed at $20.68.
Halozyme Therapeutics, Inc. (HALO) declared that it has reached a global partnershipand license agreement with AbbVie Inc. ABBV for the development and commercialization of therapies by combining the former’s ENHANZE technology platform with the latter’s proprietary compounds.
Terms of the Deal
Per the terms of the agreement, Halozyme is entitled to receive $23 million initially. Subsequently, upon the achievement of certain development, regulatory and sales-based milestones by AbbVie, Halozyme will receive milestone payments for each of up to nine partnership targets summing up to about $130 million. In addition, Halozyme is entitled to receive tiered royalties from AbbVie upon the commercialization of products under the collaboration.
Several companies in the health care sector have been caught in the recent deal-making frenzy aimed at stepping up development of their pipelines. Last month BioNTech AG inked a deal with Genmab A/S GNMSF to jointly research, develop and commercialize antibodies for cancer immunotherapy using BioNTech’s proprietary immunomodulatory antibodies and Genmab’s DuoBody technology platform.
Halozyme Therapeutics, Inc., a biotechnology company, researches, develops, and commercializes human enzymes. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter abnormal tissue structures for clinical benefit.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
